Skip to main
BDX

BDX Stock Forecast & Price Target

BDX Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 17%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Becton Dickinson is poised for long-term growth and is an attractive investment opportunity in the medical technology sector. Becton Dickinson's recent spinoff of its Lifesciences business allows for a sharpened focus on high-growth MedTech markets, driving projected mid-single digit growth. The company is committed to returning cash to shareholders through repurchases, and recent deals will positively impact its stock price. With strong sales and key launches planned, including the HemoSphere Stream Module and BD Pyxis Pro, BD is well-positioned for revenue growth and has a strong pipeline for potential acquisitions. However, the company may face risks and challenges in meeting its financial targets and achieving separation in the future. Overall, BD presents a solid investment opportunity in the medical technology sector with its strong financial performance and dedication to driving shareholder returns.

Bears say

Becton Dickinson is well-positioned to deliver high single-digit average EPS growth through FY2030 due to its strategic execution and focus on cost-efficiency initiatives. The company's strong cash distribution, ongoing dividends and share repurchases, and potential upside from the Waters Corporation merger and concentrated investments in high-growth markets further support a positive outlook. However, the potential impact of tariff uncertainty on the company's supply chain processes and its ongoing debt paydown should be monitored closely.

BDX has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 17% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Becton, Dickinson and Co. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Becton, Dickinson and Co. (BDX) Forecast

Analysts have given BDX a Buy based on their latest research and market trends.

According to 12 analysts, BDX has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $186, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $186, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Becton, Dickinson and Co. (BDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.